Mean, standard deviation (SD), and statistical parameters in Alzheimer’s disease (AD) and control cases for CE(16:1), CE(20:0), CE(20:1), CE(22:2), and CE(22:5)
Special thanks to all the participants that included professors and students of the University of Barcelona and of the EÒLIA Centre Superior d’Art Dramàtic. We would like to thank the CCiTUB (Scientific and Technological Centers of the UB) of the Universitat de Barcelona (Barcelona, Spain), for the expert and technical help using the LC-MS/MS equipment.
Rafael Franco, who is the Editor-in-Chief of Exploration of Neuroprotective Therapy, was not involved in the decision-making or the review process of this manuscript. The other authors declare no conflict of interest.
Ethical approval
This study did not involve new human or animal experiments. According to the regulations of the institution and regional government guidelines, the use de-identified data, which are already reported and readily available, does not require specific approval by an Ethics Committee.
Consent to participate
Not applicable.
Consent to publication
Not applicable.
Availability of data and materials
The data used in this study from the Kalecký et al. (2022) study, under a Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License, is provided in supplementary Table S1. The remaining supporting data of this study are available from the corresponding author upon reasonable request.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease.Lancet. 2021;397:1577–90. [DOI] [PubMed] [PMC]
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families.Science. 1993;261:921–3. [DOI] [PubMed]
Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.Cold Spring Harb Perspect Med. 2012;2:a006312. [DOI] [PubMed] [PMC]
Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS.J Lipid Res. 2009;50:S183–8. [DOI] [PubMed] [PMC]
Wong MW, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev PS. Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers.Alzheimers Dement. 2017;13:810–27. [DOI] [PubMed]
Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, et al.; Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium. Altered bile acid profile in mild cognitive impairment and Alzheimer’s disease: Relationship to neuroimaging and CSF biomarkers.Alzheimers Dement. 2019;15:232–44. [DOI] [PubMed] [PMC]
Kalecký K, German DC, Montillo AA, Bottiglieri T. Targeted Metabolomic Analysis in Alzheimer’s Disease Plasma and Brain Tissue in Non-Hispanic Whites.J Alzheimers Dis. 2022;86:1875–95. [DOI] [PubMed] [PMC]
O’Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer’s research consortium study.Arch Neurol. 2008;65:1091–5. [DOI] [PubMed] [PMC]
Phillips GR, Hancock SE, Brown SHJ, Jenner AM, Kreilaus F, Newell KA, et al. Cholesteryl ester levels are elevated in the caudate and putamen of Huntington’s disease patients.Sci Rep. 2020;10:20314. [DOI] [PubMed] [PMC]
Bantugan MA, Xian H, Solomon V, Lee M, Cai Z, Wang S, et al. Associations of ApoE4 status and DHA supplementation on plasma and CSF lipid profiles and entorhinal cortex thickness.J Lipid Res. 2023;64:100354. [DOI] [PubMed] [PMC]
Sebastiani P, Song Z, Ellis D, Tian Q, Schwaiger-Haber M, Stancliffe E, et al. A metabolomic signature of the APOE2 allele.Geroscience. 2023;45:415–26. [DOI] [PubMed] [PMC]
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.Nat Rev Neurol. 2013;9:106–18. [DOI] [PubMed] [PMC]
Faraji P, Kühn H, Ahmadian S. Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer’s Disease.J Mol Neurosci. 2024;74:62. [DOI] [PubMed] [PMC]
Chew H, Solomon VA, Fonteh AN. Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies.Front Physiol. 2020;11:598. [DOI] [PubMed] [PMC]
Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics.Front Neurosci. 2021;15:630502. [DOI] [PubMed] [PMC]
Walker KA, An Y, Moghekar A, Moaddel R, Duggan MR, Peng Z, et al. Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience.Mol Neurodegener. 2024;19:81. [DOI] [PubMed] [PMC]
Zeng Y, Cao S, Li N, Tang J, Lin G. Identification of key lipid metabolism-related genes in Alzheimer’s disease.Lipids Health Dis. 2023;22:155. [DOI] [PubMed] [PMC]
